These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1398306)

  • 41. Recombinant human erythropoietin for the treatment of refractory anemia in lymphoproliferative disorders: preliminary results.
    Tsiara St; Kaiafas P; Kapsali E; Christou L; Bourantas KL
    Eur J Haematol; 1998 May; 60(5):317-9. PubMed ID: 9654164
    [No Abstract]   [Full Text] [Related]  

  • 42. Successful immunosuppressive treatment after failure of erythropoietin therapy in two subjects with refractory anaemia.
    Muller EW; de Wolf JT; Vellenga E
    Br J Haematol; 1993 Jan; 83(1):171-2. PubMed ID: 8435327
    [No Abstract]   [Full Text] [Related]  

  • 43. Refractory anemias.
    Heller P; Fried W
    Dis Mon; 1967 Apr; ():3-38. PubMed ID: 4859724
    [No Abstract]   [Full Text] [Related]  

  • 44. Anemia and transfusion.
    Ozsoylu S
    Am J Hematol; 1994 May; 46(1):57. PubMed ID: 8184877
    [No Abstract]   [Full Text] [Related]  

  • 45. Refractory anemia with ring sideroblasts and thrombocytosis.
    Pradhan S
    Blood Res; 2017 Mar; 52(1):8. PubMed ID: 28401094
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin].
    Rodríguez JN; Prados D; Martino ML; Muñiz R
    Sangre (Barc); 1993 Aug; 38(4):340-1. PubMed ID: 8235952
    [No Abstract]   [Full Text] [Related]  

  • 47. [Neutropenia and hypotension during treatment with recombinant human erythropoietin in refractory anemia with ring sideroblasts].
    Benzadón RJ; Gurfinkel EP
    Sangre (Barc); 1990 Jun; 35(3):238-9. PubMed ID: 2396173
    [No Abstract]   [Full Text] [Related]  

  • 48. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The concept of and countermeasures in refractory anemia].
    Yoshida Y
    Nihon Naika Gakkai Zasshi; 1990 May; 79(5):593-7. PubMed ID: 2199586
    [No Abstract]   [Full Text] [Related]  

  • 50. Recombinant erythropoietin for refractory anemia with ring sideroblasts.
    Musto P; Catalano L; Andriani A; Bodenizza C; Cascavilla N; Di Renzo N; Melillo L; Cicoira L; Carotenuto M; Rotoli B
    Haematologica; 1992; 77(2):185-6. PubMed ID: 1398306
    [No Abstract]   [Full Text] [Related]  

  • 51. [The strategy for the treatment of myelodysplastic syndromes].
    Hideaki M
    Rinsho Ketsueki; 2002 Mar; 43(3):157-60. PubMed ID: 11979745
    [No Abstract]   [Full Text] [Related]  

  • 52. [Current developments in the therapy of the myelodysplastic syndrome].
    de Witte T; Hermans J; van Biezen A; Runde V; Gratwohl A
    Ned Tijdschr Geneeskd; 1995 Oct; 139(42):2135-9. PubMed ID: 7477578
    [No Abstract]   [Full Text] [Related]  

  • 53. Erythropoietin: physiologic basis for clinical applications.
    Schuster SJ; Caro J
    Vox Sang; 1993; 65(3):169-79. PubMed ID: 8249358
    [No Abstract]   [Full Text] [Related]  

  • 54. Recombinant growth factors.
    Goodnough LT; Anderson KC
    Transfus Sci; 1995 Mar; 16(1):45-62. PubMed ID: 10155704
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.